Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Erythromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: minor gastrointestinal symptoms · pityriasis rosea
Erythromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo (moderate certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea
Azithromycin showed no clear difference in the proportion of participants with resolution of itch within 2… compared with placebo or vitamins (moderate certainty).
1 finding from 1 review
Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Azithromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo or vitamins (low certainty).
1 finding from 1 review
Minor participant‐reported adverse events not requiring withdrawal of the treatment: Mild abdominal pain. · pityriasis rosea
Azithromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo or vitamins (moderate certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea
Acyclovir probably leads to lower proportion of participants with resolution of itch within 2 weeks,… compared with placebo, vitamins, or no treatment (moderate certainty).
1 finding from 1 review
Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Acyclovir probably leads to higher the proportion of participants with good or excellent rash… compared with placebo, vitamins, or no treatment (moderate certainty).
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · pityriasis rosea
Acyclovir showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo, vitamins, or no treatment (moderate certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review